Breaking News

OsoBio Appoints Lab Director

By Kristin Brooks | February 24, 2014

Stoker brings 20 years of pharmaceutical quality control experience

Paul W. Stoker, Ph.D., has been appointed director of OsoBio’s chemistry and microbiology laboratories. Dr. Stoker replaces Kathleen Larese, who now serves as director of technical operations.
As part of the company’s quality control department, the labs are responsible for testing the in-process and finished products, as well as raw materials and components, for the company’s cGMP sterile manufacturing operations. The labs are also responsible for environmental monitoring and analytical method development.
Dr. Stoker brings 20 years of professional experience managing pharmaceutical labs responsible for quality control. Most recently, he served as director of the quality control lab at Dendreon. Prior to that, he directed quality control and analytical laboratories for Nektar Therapeutics.
“While continuous quality compliance is key to OsoBio’s business success, it’s even more important to the patients who rely upon the medications we manufacture – and we try to never lose sight of that fact,” said Milton Boyer, president of OsoBio. “Paul will lead a team of scientists who are knowledgeable, capable and highly committed to integrity – delivering excellence to both our clients and the patients we collectively serve.”
blog comments powered by Disqus
  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • 2015 Contracting & Outsourcing Wrap-up

    2015 Contracting & Outsourcing Wrap-up

    Kristin Brooks, Contract Pharma||September 30, 2015
    A huge success, with another year of record attendance, sold-out exhibit hall, and a great line up of informative sessions

  • Setting a Precedent for Biosimilars in the U.S.

    Setting a Precedent for Biosimilars in the U.S.

    Kristin Brooks, Contract Pharma||May 19, 2015
    Niall Dinwoodie of Charles River discusses several key industry issues on biosimilars and addresses some of the development and regulatory hurdles that remain